CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Alteplase +1 moredrug
Likely dose
Alteplase 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00284739
NCT00284739Phase 2Completed
CompareCT.gov

Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses

Kaiser Permanente·interventional·Posted Feb 1, 2006·Updated Feb 26, 2015

In Brief

A Phase 2 clinical trial evaluating Alteplase and saline for Abdominal Abscess and Pelvic Abscess. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Intracavitary injection of low dose alteplase into loculated abdominopelvic abscesses will reduce the duration of percutaneous drainage and increase the proportion of successful drainages.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAbdominal Abscess, Pelvic Abscess
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 1, 2006
Enrollment StartFeb 1, 2006
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 20.4 years ago

Interventions

Alteplasedrug

2mg or 4mg given twice daily for three days into loculated abscess

salineother

saline injection twice daily for three days